| 000 | 01876 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250515103654.0 | ||
| 264 | 0 | _c20080128 | |
| 008 | 200801s 0 0 eng d | ||
| 022 | _a0889-2229 | ||
| 024 | 7 |
_a10.1089/aid.2007.0091 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNussenblatt, Veronique | |
| 245 | 0 | 0 |
_aImmunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients. _h[electronic resource] |
| 260 |
_bAIDS research and human retroviruses _cNov 2007 |
||
| 300 |
_a1354-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAlanine Transaminase _xblood |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAspartate Aminotransferases _xblood |
| 650 | 0 | 4 | _aCD4 Lymphocyte Count |
| 650 | 0 | 4 |
_aDrug Resistance, Viral _ximmunology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xcomplications |
| 650 | 0 | 4 |
_aHepacivirus _xdrug effects |
| 650 | 0 | 4 |
_aHepatitis C _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferons _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMolecular Sequence Data |
| 650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
| 650 | 0 | 4 | _aViral Load |
| 700 | 1 | _aMcLaughlin, Mary | |
| 700 | 1 | _aRehm, Catherine A | |
| 700 | 1 | _aLempicki, Richard A | |
| 700 | 1 | _aBrann, Terry | |
| 700 | 1 | _aYang, Jun | |
| 700 | 1 | _aProschan, Michael | |
| 700 | 1 | _aHighbarger, Helene C | |
| 700 | 1 | _aDewar, Robin L | |
| 700 | 1 | _aImamichi, Tom | |
| 700 | 1 | _aKoratich, Chad | |
| 700 | 1 | _aNeumann, Avidan U | |
| 700 | 1 | _aMasur, Henry | |
| 700 | 1 | _aPolis, Michael A | |
| 700 | 1 | _aKottilil, Shyam | |
| 773 | 0 |
_tAIDS research and human retroviruses _gvol. 23 _gno. 11 _gp. 1354-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1089/aid.2007.0091 _zAvailable from publisher's website |
| 999 |
_c17693882 _d17693882 |
||